10-12 October, 2017
Frankfurt, Germany

Day One
Wednesday 11th October, 2017

Day Two
Thursday 12th October, 2017

Chair’s Opening Remarks

  • Peter Traber Chief Executive Officer & Chief Medical Officer, Galectin Therapeutics

Winning the Dash for NASH: Harnessing Recent Advances to Accelerate Drug Development

Keynote: How is the Field Conquering this Global Health Crisis? Review Latest Advancements in NASH Drug Development


• Comprehensively explore recent developments in NASH drug development
• Evaluate the regulatory feedback on the development of late stage clinical NASH candidates
• Discuss the current challenges and how we will progress as a field

Key Opinion Leaders Discuss: Challenges & Opportunities in NASH Drug Development


• Enhancing clinical trial design to improve patient enrolment
• Explore pioneering advances in non-invasive diagnostic technologies
• Harnessing the power of combinations – discuss the opportunity to combine anti-inflammatory and anti-fibrotic compounds

Speed Networking


This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Get face-to-face time with many of the brightest minds working in the NASH field and establish meaningful business relationships.

Morning Refreshments

Identify & Validate Druggable & Clinically Relevant NASH Mechanisms

Exploring Key Regulators in NASH


• Enhance understanding of known and novel regulators in NASH
• Explore the design and testing of single stranded antisense molecules that target specific proteins, which could be a key regulator in NASH development
• Review the exploratory and pre-clinical development research

Targeting Multiple Fibrogenic Pathways with the NOX1/4 Inhibitor GKT831


• Discover NADPH oxidases (NOX)
• Explore GKT831’s mechanism of action – targeting multiple fibrogenic pathways
• Anti-fibrotic efficacy achieved in multiple preclinical models of liver disease (NASH, PBC)
• Gain a comprehensive understanding of clinical efficacy and safety profiles
• Overview of ongoing phase 2 trial in primary biliary cholangitis

Lunch & Networking

Analyse Recent Progress in Targeting NASH Fibrosis – Novel Inhibitors of Galectin-3


• Advance your understanding of how galectin-3 plays central role in fibrosis process
• Examine how novel galectin-3 inhibitors reduce liver fibrosis

Better Recapitulate Human NASH Preclinically & Effectively Translate into Clinical Development

Truthful In-Depth Review of the Advantages & Disadvantages of Preclinical Models


• Overview of the wide range of rodent models currently used to model NAFLD/NASH, from diet to genetic & chemical models
• How should we be effectively evaluating NAFLD/NASH therapies from the plethora of rodent models available? Can we draw robust conclusions from an in-depth comparison of running animal models in parallel?
• Identify an industry standard model? If we agree, how do we get there?

Afternoon Refreshments & Networking

Better Recapitulate Human NASH Preclinically & Effectively Translate into Clinical Development

Modeling Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue

  • Alice E Chen Associate Director, R&D, Tissue Applications, Organovo


  • ExVive™ Human Liver Tissue, a human in vitro 3D bioprinted liver model comprising primary human hepatocytes, hepatic stellate cells, and endothelial cells, exhibits a complex multicellular architecture more similar to that of native liver and retains metabolic competence and liver-specific functions for at least 4 weeks in culture.
  • Steatosis can be induced via chronic exposure to lipids in the presence of high glucose, leading to increased incidence of lipid vesicles positive for Oil Red O and the lipid droplet-associated protein, Perilipin 5.
  • Incorporation of both stellate and Kupffer cells into the tissues, concomitant with activation via inflammatory inducers and nutrient overload, leads to activation of stellate cells, inflammatory cytokine release, and an increase in extracellular matrix deposition and fibrosis, characteristic of NASH.
  • Together, these features suggest that 3D liver tissues hold promise for the study of complex, chronic conditions such as NASH, enabling the discovery of novel therapeutics, biomarkers, and safety assessment of drugs in a disease-relevant background.

Preclinical Model & Methods Optimization: Lessons from Developing 2nd Generation FXR Agonists for NASH

  • Jonathan Roth Senior Director, In Vivo Pharmacology , Intercept Pharmaceuticals


• Optimize in vivo experimental design and methods to detect histological treatment effects
• Discuss advantages and disadvantages of qualitative vs. quantitative imaging
• Highlight findings with FXR agonists

Chair’s Closing Remarks

  • Peter Traber Chief Executive Officer & Chief Medical Officer, Galectin Therapeutics